HALO
NEUTRAL
$67.82
Live
Halozyme Therapeutics, Inc. · NASDAQ
Target $84.89
(+25.2%)
$47.5
52W Range
$82.22
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 11, 2026
Market cap
$8.03B
P/E
26.49
ROE
153.6%
Profit margin
22.7%
Debt/Equity
44.6
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
HALO presents a stark contrast between operational efficiency and valuation sanity. While the Piotroski F-Score of 4/9 indicates stable financial health, the stock trades at a massive premium to its Graham Number ($4.88) and Intrinsic Value ($17.92). Despite exceptional operating margins (56.31%) and strong revenue growth (51.6%), the recent collapse in EPS (-114% Q/Q) and aggressive insider selling by the CEO and COO create significant headwinds that offset the bullish analyst consensus.
Key Strengths
Exceptional profitability with 77.79% gross margins and 56.31% operating margins
Strong top-line momentum with 51.60% YoY revenue growth
Very high Return on Equity (153.59%) indicating efficient capital use
Robust short-term liquidity with a Current Ratio of 4.66
Strong analyst support with a mean target price of $84.89
Key Risks
Extreme valuation disconnect with a Price/Book ratio of 163.82
Severe recent earnings deterioration (EPS growth -122.6% YoY)
Bearish insider sentiment with significant selling by the CEO and COO
Technical trend is currently 0/100 (Bearish)
Significant gap between current price and deterministic fair value models
AI Fair Value Estimate
Based on comprehensive analysis
$42.5
-37.3% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
41
Moderate
15
55
75
60
0
AI Verdict
Speculative Hold
Key drivers: High operational margins, Revenue growth, Valuation bubble, Insider dumping
Confidence
90%
Value
15/100
Ref P/E, PEG, Graham Number
Positives
- Low Forward P/E (6.92) suggests future earnings recovery
Watchpoints
- P/B of 163.82 is extreme
- Price is ~13x the Graham Number
Future
55/100
Ref Growth rates
Positives
- Strong YoY revenue growth (51.6%)
- Bullish analyst price targets
Watchpoints
- Recent EPS crash (-114% Q/Q)
- Bearish technical trend
Past
75/100
Ref Historical trends
Positives
- Strong 3Y (+84.6%) and 5Y (+57.9%) price appreciation
- Consistent history of beating estimates over 25 quarters
Watchpoints
- Recent trend of missing estimates (2/4 last 4 quarters)
Health
60/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Piotroski F-Score 4/9 (Stable)
- High Current and Quick ratios
Watchpoints
- Debt/Equity ratio is high (44.60)
- Lack of Altman Z-Score data
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$67.82
Analyst Target
$84.89
Upside/Downside
+25.2%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for HALO and closest competitors.
Updated 2026-04-10
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
HALO
Halozyme Therapeutics, Inc.
Primary
|
+57.9% | +84.6% | +17.5% | +5.8% | +2.0% | +5.2% |
|
AVTR
Avantor, Inc.
Peer
|
-61.5% | -48.8% | -46.0% | -17.0% | +4.6% | -3.0% |
|
CYTK
Cytokinetics, Incorporated
Peer
|
+170.7% | +87.1% | +81.9% | +8.8% | +4.9% | -0.7% |
|
BIO
Bio-Rad Laboratories, Inc.
Peer
|
-49.6% | -35.1% | -15.9% | +12.3% | -1.7% | -5.4% |
|
ATR
AptarGroup, Inc.
Peer
|
-3.9% | +15.9% | -20.1% | -21.4% | +2.6% | +1.0% |
HAL
Halozyme Therapeutics, Inc.
Primary
5Y
+57.9%
3Y
+84.6%
1Y
+17.5%
6M
+5.8%
1M
+2.0%
1W
+5.2%
AVT
Avantor, Inc.
Peer
5Y
-61.5%
3Y
-48.8%
1Y
-46.0%
6M
-17.0%
1M
+4.6%
1W
-3.0%
CYT
Cytokinetics, Incorporated
Peer
5Y
+170.7%
3Y
+87.1%
1Y
+81.9%
6M
+8.8%
1M
+4.9%
1W
-0.7%
BIO
Bio-Rad Laboratories, Inc.
Peer
5Y
-49.6%
3Y
-35.1%
1Y
-15.9%
6M
+12.3%
1M
-1.7%
1W
-5.4%
ATR
AptarGroup, Inc.
Peer
5Y
-3.9%
3Y
+15.9%
1Y
-20.1%
6M
-21.4%
1M
+2.6%
1W
+1.0%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
26.49
Forward P/E
6.92
PEG Ratio
N/A
P/B Ratio
163.82
P/S Ratio
5.75
EV/Revenue
7.19
EV/EBITDA
11.18
Market Cap
$8.03B
Profitability
Profit margins and return metrics
Profit Margin
22.69%
Operating Margin
56.31%
Gross Margin
77.79%
ROE
153.59%
ROA
22.24%
Growth
Revenue and earnings growth rates
Revenue Growth
+51.6%
Earnings Growth
N/A
Q/Q Revenue Growth
+51.6%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
44.6
High debt
Current Ratio
4.66
Strong
Quick Ratio
3.3
Excellent
Cash/Share
$1.21
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.5B
Gross Margin
82.6%
Op. Margin
53.3%
Net Margin
-31.3%
Total Assets
$2.5B
Liabilities
$2.5B
Equity
$0.0B
Debt/Equity
50.73x
Operating CF
$0.2B
CapEx
$-0.3B
Free Cash Flow
$-0.1B
FCF Yield
-32%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-05
$N/A
2026-02-17
$-0.24
-110.9% surprise
2025-11-03
$1.72
+5.5% surprise
2025-08-05
$1.54
+21.4% surprise
Healthcare Sector Comparison
Comparing HALO against 226 companies in the Healthcare sector
(19 bullish, 76 neutral, 131 bearish)
P/E Ratio
26.49
This Stock
vs
45.29
Sector Avg
-41.5%
(Discount)
Return on Equity (ROE)
153.59%
This Stock
vs
-40.43%
Sector Avg
-479.9%
(Below Avg)
Profit Margin
22.69%
This Stock
vs
-18.65%
Sector Avg
-221.7%
(Weaker)
Debt to Equity
44.6
This Stock
vs
4.61
Sector Avg
+868.0%
(Higher)
Revenue Growth
51.6%
This Stock
vs
97.21%
Sector Avg
-46.9%
(Slower)
Current Ratio
4.66
This Stock
vs
3.51
Sector Avg
+32.8%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
HALO
Halozyme Therapeutics, Inc.
|
NEUTRAL | $8.03B | 26.49 | 153.6% | 22.7% | $67.82 | |
|
AVTR
Avantor, Inc.
|
BEARISH | $8.05B | - | -1.5% | -1.2% | $11.8 | Compare |
|
CYTK
Cytokinetics, Incorporated
|
NEUTRAL | $8.06B | - | -% | -% | $65.48 | Compare |
|
BIO
Bio-Rad Laboratories, Inc.
|
NEUTRAL | $8.0B | - | -9.5% | -26.4% | $296.57 | Compare |
|
ATR
AptarGroup, Inc.
|
NEUTRAL | $8.3B | 19.97 | 15.6% | 11.5% | $126.0 | Compare |
HALO
Halozyme...
NEUTRAL
Mkt Cap
$8.0B
P/E
26.5
ROE
153.6%
Price
$67.82
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-06 | TORLEY HELEN I | Chief Executive Officer | Sale | 10,000 | $634,982 |
| 2026-04-06 | TORLEY HELEN I | Chief Executive Officer | Option Exercise | 10,000 | $120,700 |
| 2026-04-02 | TORLEY HELEN I | Chief Executive Officer | Sale | 40,000 | $2,592,237 |
| 2026-04-02 | TORLEY HELEN I | Chief Executive Officer | Option Exercise | 40,000 | $482,800 |
| 2026-03-10 | CAUDILL CORTNEY | Chief Operating Officer | Sale | 28,857 | $1,955,160 |
| 2026-03-10 | CAUDILL CORTNEY | Chief Operating Officer | Option Exercise | 21,546 | $722,006 |
| 2026-03-04 | TORLEY HELEN I | Chief Executive Officer | Sale | 50,000 | $3,476,157 |
| 2026-03-04 | TORLEY HELEN I | Chief Executive Officer | Option Exercise | 50,000 | $603,500 |
| 2026-02-23 | SNYDER MARK HOWARD | Officer | Stock Award | 12,343 | - |
| 2026-02-23 | LABROSSE NICOLE | Chief Financial Officer | Stock Award | 12,020 | - |
| 2026-02-23 | TORLEY HELEN I | Chief Executive Officer | Stock Award | 39,193 | - |
| 2026-02-20 | CAUDILL CORTNEY | Chief Operating Officer | Stock Award | 2,666 | - |
| 2026-02-13 | SNYDER MARK HOWARD | Officer | Stock Award | 16,812 | - |
| 2026-02-13 | LABROSSE NICOLE | Chief Financial Officer | Stock Award | 23,773 | - |
| 2026-02-13 | TORLEY HELEN I | Chief Executive Officer | Stock Award | 89,055 | - |
TORLEY HELEN I
Chief Executive Officer
2026-04-06
10,000 shares
·
$634,982
TORLEY HELEN I
Chief Executive Officer
2026-04-06
10,000 shares
·
$120,700
TORLEY HELEN I
Chief Executive Officer
2026-04-02
40,000 shares
·
$2,592,237
TORLEY HELEN I
Chief Executive Officer
2026-04-02
40,000 shares
·
$482,800
CAUDILL CORTNEY
Chief Operating Officer
2026-03-10
28,857 shares
·
$1,955,160
CAUDILL CORTNEY
Chief Operating Officer
2026-03-10
21,546 shares
·
$722,006
TORLEY HELEN I
Chief Executive Officer
2026-03-04
50,000 shares
·
$3,476,157
TORLEY HELEN I
Chief Executive Officer
2026-03-04
50,000 shares
·
$603,500
SNYDER MARK HOWARD
Officer
2026-02-23
12,343 shares
LABROSSE NICOLE
Chief Financial Officer
2026-02-23
12,020 shares
TORLEY HELEN I
Chief Executive Officer
2026-02-23
39,193 shares
CAUDILL CORTNEY
Chief Operating Officer
2026-02-20
2,666 shares
SNYDER MARK HOWARD
Officer
2026-02-13
16,812 shares
LABROSSE NICOLE
Chief Financial Officer
2026-02-13
23,773 shares
TORLEY HELEN I
Chief Executive Officer
2026-02-13
89,055 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
9 analysts
Benchmark
2026-02-19
Buy
Buy
Wells Fargo
2026-02-19
Equal-Weight
Equal-Weight
TD Cowen
2026-01-08
Buy
Buy
HC Wainwright & Co.
2025-12-19
Buy
Buy
HC Wainwright & Co.
2025-11-28
Buy
Buy
Goldman Sachs
2025-11-18
Neutral
Neutral
Citizens
2025-11-04
Market Outperform
Market Outperform
JP Morgan
2025-10-27
Neutral
Neutral
Morgan Stanley
2025-10-20
Overweight
Overweight
HC Wainwright & Co.
2025-10-15
Buy
Buy
Past News Coverage
Recent headlines mentioning HALO from our newsroom.
Newest → oldest
No matching news yet.